Shots:

• VaxEquity can receive ~$195M in development- approval- and sales-based milestones along with royalties per program & is also eligible to receive an equity investment from AstraZeneca for the development of the saRNA platform
• The focus of the collaboration is to optimize and validate VaxEquity’s saRNA platform to advance novel therapeutic programs
• AstraZeneca support VaxEquity with R&D funding to advance any of the research programs into its pipeline & gets an option to collaborate with VaxEquity on up to 26 drug targets

Ref: AstraZeneca | Image: The Scientist Magazine